ArticleDrug and alcohol dependence2010
Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy.
Article in Drug and alcohol dependence, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 2 syntheses or guidelines pooled it, 127 citations in OpenAlex.
- Diversity inclusion in United States opioid pharmacological treatment trials: A systematic review.Experimental and clinical psychopharmacology · 2021Pooled it
- Oral substitution treatment of injecting opioid users for prevention of HIV infection.The Cochrane database of systematic reviews · 2011Pooled it
- Treatment outcomes among a cohort of African American buprenorphine patients: Follow-up at 12 months.The American journal of drug and alcohol abuse · 2018Trial
- A randomized clinical trial of buprenorphine for prisoners: Findings at 12-months post-release.Drug and alcohol dependence · 2017Trial
- A randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults.Addiction (Abingdon, England) · 2016Trial
- Safety of a Rapidly Dissolving Buprenorphine/Naloxone Sublingual Tablet (BNX-RDT) for Treatment of Opioid Dependence: A Multicenter, Open-label Extension Study.Journal of addiction medicineTrial
- Strategies for improving treatment retention for buprenorphine/naloxone for opioid use disorder: a qualitative study of issues and recommendations from prescribers.Addiction science & clinical practice · 2024Article
- Research Priorities for Expansion of Opioid Use Disorder Treatment in the Community Pharmacy.Substance abuse · 2023Article
- Viewing Then Doing?: Problem-Solving Court Coordinators' Perceptions of Medications for Opioid Use Disorders from a Nationally Representative Survey in the United States.Substance use & misuse · 2023Article
- Association of chronic non-cancer pain status and buprenorphine treatment retention among individuals with opioid use disorder: Results from electronic health record data.Drug and alcohol dependence reports · 2022Article
- The impact of self-help groups on successful substance use treatment completion for opioid use: An intersectional analysis of race/ethnicity and sex.Journal of substance abuse treatment · 2022Article
- Association Between Receipt of Antidepressants and Retention in Buprenorphine Treatment for Opioid Use Disorder: A Population-Based Retrospective Cohort Study.The Journal of clinical psychiatry · 2022Article
- Associations of retention on buprenorphine for opioid use disorder with patient characteristics and models of care in the primary care setting.Journal of substance abuse treatment · 2021Article
- A machine learning based two-stage clinical decision support system for predicting patients' discontinuation from opioid use disorder treatment: retrospective observational study.BMC medical informatics and decision making · 2021Observational
- The effectiveness and value of digital health technologies as an adjunct to medication-assisted therapy for opioid use disorder.Journal of managed care & specialty pharmacy · 2021Article
- Tramadol for the Management of Opioid Withdrawal: A Systematic Review of Randomized Clinical Trials.Cureus · 2020Review
- Buprenorphine Treatment By Primary Care Providers, Psychiatrists, Addiction Specialists, And Others.Health affairs (Project Hope) · 2020Article
- Impact Of Long-Term Buprenorphine Treatment On Adverse Health Care Outcomes In Medicaid.Health affairs (Project Hope) · 2020Article
- Long-term treatment retention in West Virginia's comprehensive opioid addiction treatment (COAT) program.Journal of the neurological sciences · 2020Review
- Acute Care, Prescription Opioid Use, and Overdose Following Discontinuation of Long-Term Buprenorphine Treatment for Opioid Use Disorder.The American journal of psychiatry · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundBuprenorphine/naloxone was approved by the FDA for office-based opioid maintenance therapy (OMT), with little long-term follow-up data from actual office-based practice. 18-Month outcome data on the office-based use of buprenorphine/naloxone (bup/nx) and the impact of socioeconomic status and other patient characteristics on the duration and clinical effects of bup/nx are reported.
methodsThis retrospective chart review and cross-sectional telephone interview provide treatment retention of opioid-dependent patients receiving bup/nx-OMT in an office-based setting. 176 opioid-dependent patients from two different socioeconomic groups (high and low SES) were begun on bup/nx, started intensive outpatient treatment, and followed-up after a minimum of 18 months (18-42 months) by telephone interview to assess treatment outcome.
results110 subjects (67%) completed the interview, 77% remained on bup/nx with no difference in retention between high and low SES groups. Those on bup/nx at follow-up were more likely to report abstinence, to be affiliated with 12-step recovery, to be employed and to have improved functional status.
conclusionsBup/nx-OMT is a viable treatment option and when coupled with a required abstinence oriented addiction counseling program is effective in promoting abstinence, self-help group attendance, occupational stability, and improved psychosocial outcomes in both low SES and high SES patient populations over an 18-42-month period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.